

Cotellic (cobimetinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Cotellic (cobimetinib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Cotellic (cobimetinib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of unresectable or metastatic Melanoma (Label, NCCN 1, 2A); **AND**
 - A. Individual has BRAF V600E or V600K mutation (or BRAF V600 activating mutation); **AND**
 - B. Individual is using in combination with vemurafenib with or without atezolizumab;

OR

- II. Individual has a diagnosis of Central Nervous System – Adult Glioma cancer (NCCN 2A); **AND**
 - A. Individual is using in combination with vemurafenib; **AND**
 - B. Individual is using for primary CNS cancer; **AND**
 - C. Individual has BRAF V600E mutation;

OR

- III. Individual has a diagnosis for a histiocytic neoplasm (Label, NCCN 2A); **AND**
 - A. Individual is using Cotellic (cobimetinib) as a single agent.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 24, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2021 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. June 24, 2022.
 - a. Central Nervous System Cancers. V1.2022. Revised June 2, 2022.
 - b. Cutaneous Melanoma. V3.2022. Revised April 11, 2022.
 - c. Histiocytic Neoplasms. V1.2022. Revised May 20, 2022.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.